| Imaging of diabetic retinopathy |
5 |
| Treatment of diabeticmacular edema |
3 |
| Clinical staging of diabetic retinopathy |
3 |
| Type 3c diabetes mellitus-prevalence, diagnosis, special aspects of treatment |
2 |
| Digitalization in clinical practice |
2 |
| Big data for personalized diabetes prevention |
2 |
| Which patients with type 2 diabetes receive new antidiabetic drugs? Data analysis of the registries Diabetes-Patienten-Verlaufsdokumentation and Diabetes-Versorgungs-Evaluation |
2 |
| Diabetes subphenotypes |
2 |
| Pediatrics-the driving factor for technological advancements in diabetology |
1 |
| Asymptomatic early stage type 1 diabetes. Oral insulin as a preventive treatment |
1 |
| Global Platformfor the Prevention of Autoimmune Diabetes (GPPAD) Early detection and primary prevention of type 1 diabetes |
1 |
| Pathophysiology of diabetic peripheral Neuropathy (DN), role of inflammation and iron metabolism |
1 |
| Neuropathy in diabetes: always diabetic polyneuropathy? |
1 |
| Magnetic resonance neurography in diabetic polyneuropathy |
1 |
| Pathophysiology of pain in diabetic polyneuropathy |
1 |
| Chronic inflammatory demyelinating polyradiculoneuropathy in diabetes Manifestation in pre-existing diabetic polyneuropathy |
1 |
| Pain treatment in diabetic polyneuropathy An update |
1 |
| Update on education and empowerment |
1 |
| Cardiovascular disease in diabetes. Modulation of inflammatory response as a new treatment option |
1 |
| Early diagnosis of type 1 diabetes in the Fr1da study Diagnosis at an asymptomatic stage |
1 |
| Systemic treatment of diabetic retinopathy-the medical perspective |
1 |
| Do-it-yourself artificial pancreas - technology hype or real benefits? |
1 |
| Genetic background of type 2 diabetes |
1 |
| Long-term consequences and prevention strategies for women with a history of gestational diabetes |
1 |
| Diabetes at a glance-National diabetes surveillance |
1 |
| Microbiome, inflammation and insulin resistance |
1 |
| Special aspects of type 1 diabetes in children and adolescents. From childhood to adulthood |
1 |
| Chronic obstructive pulmonary disease and diabetes |
0 |
| Diabetes and sleep apnea |
0 |
| Interventions for diabetic heart disease |
0 |
| Diabetes and restrictive lung diseases/fibrosis |
0 |
| Diabetes and impaired pulmonary function |
0 |
| Mucormycosis in patients with diabetes mellitus |
0 |
| Diabetic foot osteomyelitis. A diagnostic and therapeutic challenge |
0 |
| Diabetes mellitus and the immune response to pyogenic infections |
0 |
| Diabetes and tuberculosis. A short review |
0 |
| Type 1 diabetes mellitus and pregnancy |
0 |
| Attempted suicide with the SGLT2 inhibitor empagliflozin saves patient's life |
0 |
| SGLT2 inhibitors as standard medication for at-risk patients |
0 |
| Nephroprotection via SGLT2 inhibition |
0 |
| Diabetes treatment in kidney disease. Special considerations and limitations |
0 |
| Epidemiology and pathogenesis of diabetic kidney disease |
0 |
| Omentin and cardiometabolic risk |
0 |
| Adipose tissue inflammation |
0 |
| Sarcopenic obesity and inflammation |
0 |
| Glucagon, the forgotten hormone |
0 |
| Comorbidities of type 2 diabetes. Data from family physicians' offices and diabetes practices in Germany |
0 |
| Knowledge derived from disease management program data |
0 |
| Incidence of late complications of diabetesmellitus. St. Vincent trends |
0 |
| Effectiveness of glucose-lowering therapy in type 2 diabetes in primary care |
0 |
